FR2248025A2 - Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant - Google Patents

Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant

Info

Publication number
FR2248025A2
FR2248025A2 FR7337806A FR7337806A FR2248025A2 FR 2248025 A2 FR2248025 A2 FR 2248025A2 FR 7337806 A FR7337806 A FR 7337806A FR 7337806 A FR7337806 A FR 7337806A FR 2248025 A2 FR2248025 A2 FR 2248025A2
Authority
FR
France
Prior art keywords
acyl
contg
vaccine
adjuvant
muramic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7337806A
Other languages
English (en)
Other versions
FR2248025B2 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to FR7337806A priority Critical patent/FR2248025A2/fr
Priority to US05/516,991 priority patent/US4186194A/en
Priority to GB45807/74A priority patent/GB1496332A/en
Priority to NL7413855A priority patent/NL7413855A/xx
Priority to DE19742450355 priority patent/DE2450355A1/de
Priority to BE149800A priority patent/BE821385A/fr
Publication of FR2248025A2 publication Critical patent/FR2248025A2/fr
Application granted granted Critical
Publication of FR2248025B2 publication Critical patent/FR2248025B2/fr
Priority to US05/906,002 priority patent/US4235771A/en
Priority to US06/135,935 priority patent/US4327085A/en
Priority to US06/135,928 priority patent/US4323559A/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR7337806A 1973-10-23 1973-10-23 Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant Granted FR2248025A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR7337806A FR2248025A2 (en) 1973-10-23 1973-10-23 Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant
US05/516,991 US4186194A (en) 1973-10-23 1974-10-22 Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
NL7413855A NL7413855A (nl) 1973-10-23 1974-10-23 Werkwijze voor het bereiden van een vaccin en van hulpmiddelen die dit vaccin bevatten.
DE19742450355 DE2450355A1 (de) 1973-10-23 1974-10-23 Aus n-acyl-muraminsaeurederivaten gebildete adjuvanzien und diese enthaltende impfstoffe
GB45807/74A GB1496332A (en) 1973-10-23 1974-10-23 Vaccine adjuvants
BE149800A BE821385A (fr) 1973-10-23 1974-10-23 Agents adjuvants formes par les derives de l'acide n-acyl-muramique et compositions de vaccins contenant ces agents adjuvants
US05/906,002 US4235771A (en) 1973-10-23 1978-05-15 Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US06/135,935 US4327085A (en) 1973-10-23 1980-03-31 Biologically active compositions and methods of use
US06/135,928 US4323559A (en) 1973-10-23 1980-03-31 Compounds derived from N-acetyl-nor-muramyl-L-alanyl-D-isoglutamic acid and other compounds and biologically active compositions containing such compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7337806A FR2248025A2 (en) 1973-10-23 1973-10-23 Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant

Publications (2)

Publication Number Publication Date
FR2248025A2 true FR2248025A2 (en) 1975-05-16
FR2248025B2 FR2248025B2 (fr) 1977-08-19

Family

ID=9126818

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7337806A Granted FR2248025A2 (en) 1973-10-23 1973-10-23 Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant

Country Status (2)

Country Link
BE (1) BE821385A (fr)
FR (1) FR2248025A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
FR2466455A2 (fr) * 1979-10-05 1981-04-10 Anvar Nouveaux composes hydrosolubles, provenant d'extraits de streptomyces stimulosus, leur obtention, leur application a titre d'adjuvants immunologiques et compositions les contenant
EP0027260A3 (en) * 1979-10-11 1981-06-03 Fujisawa Pharmaceutical Co. Ltd. New peptides, processes for their preparation and pharmaceutical compositions containing them
FR2482959A2 (fr) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Nouveaux tripeptides, leur preparation et les medicaments qui les contiennent
FR2482958A2 (fr) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Nouveaux tripeptides, leur preparation et les medicaments qui les contiennent
EP0025842A3 (en) * 1979-07-31 1982-02-10 Fujisawa Pharmaceutical Co. Ltd. Peptides, process for their preparation, their pharmaceutical compositions and their intermediates
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310514A (en) 1980-05-05 1982-01-12 Merck & Co., Inc. Immunologically active dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose derivatives and methods of preparation

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
FR2482959A2 (fr) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Nouveaux tripeptides, leur preparation et les medicaments qui les contiennent
FR2482958A2 (fr) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Nouveaux tripeptides, leur preparation et les medicaments qui les contiennent
EP0025842A3 (en) * 1979-07-31 1982-02-10 Fujisawa Pharmaceutical Co. Ltd. Peptides, process for their preparation, their pharmaceutical compositions and their intermediates
FR2466455A2 (fr) * 1979-10-05 1981-04-10 Anvar Nouveaux composes hydrosolubles, provenant d'extraits de streptomyces stimulosus, leur obtention, leur application a titre d'adjuvants immunologiques et compositions les contenant
EP0027260A3 (en) * 1979-10-11 1981-06-03 Fujisawa Pharmaceutical Co. Ltd. New peptides, processes for their preparation and pharmaceutical compositions containing them
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant
EP0089266A1 (fr) * 1982-03-09 1983-09-21 Pierre Fabre S.A. Procédé de préparation de protéoglycanes immunostimulants inducteurs d'interféron, protéoglycanes obtenus et médicament les contenant

Also Published As

Publication number Publication date
FR2248025B2 (fr) 1977-08-19
BE821385A (fr) 1975-04-23

Similar Documents

Publication Publication Date Title
NO930938D0 (no) Forbedrede vaksiner
IL91007A0 (en) Synthetic vaccine against aids virus
DE3583293D1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
ES408766A1 (es) Procedimiento para preparar agentes inmunologicos.
RU2000116260A (ru) Вакцины с адъювантом ltb
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
BR9509190A (pt) Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano
DK472988A (da) Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi
MXPA01011660A (es) Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.
FR2248025A2 (en) Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant
DK0578293T3 (da) E. coli-P-fimbrin som immunogent bæresystem mod GnRH
CA2431188A1 (fr) Compositions pharmaceutiques permettant d'augmenter l'immunogenecite d'antigenes peu immunogenes
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
FR2324311A1 (fr) Adjuvants immunologiques solubles dans l'eau, notamment pour vaccins, obtenus a partir de mycobacteries et autres micro-organismes
GB1256456A (en) Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
MX2021014102A (es) Terapia de vacuna anti-abeta.
DK0725653T3 (da) Vaccinepræparater
GB1441098A (en) Biological preparations
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
GB1256457A (en) Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation
IE873268L (en) Conjugate vaccine
JP3071877B2 (ja) 経口寛容誘導能を有する低アレルゲン性酵素分解ペプチド組成物
FR2288527A2 (fr) Compositions contenant de la n-acetyl-muramyl- l-alanyl - d-isoglutamine ou de l'acide n-acetyl-muramyl-l-alanyl - d-glutamique, exemptes d'huile et ayant des proprietes adjuvantes
SU1538305A1 (ru) Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней